Pacira Pharmaceuticals Stock
Price
Target price
€18.00
€18.00
-5.260%
-1.0
-5.260%
€44.57
19.07.24 / Stuttgart Stock Exchange
WKN: A1H68T / Symbol: PCRX / Name: Pacira Pharma / Stock / Pharmaceuticals / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pacira Pharmaceuticals Stock
Pacira Pharmaceuticals took a tumble today and lost -€1.000 (-5.260%).
The stock is an absolute favorite of our community with 21 Buy predictions and no Sell predictions.
Based on the current price of 18.0 € the target price of 44 € shows a potential of 144.44% for Pacira Pharmaceuticals which would more than double the current price.
Pros and Cons of Pacira Pharmaceuticals in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pacira Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pacira Pharmaceuticals | -5.260% | -9.091% | -31.298% | -45.122% | -39.597% | -63.115% | -48.820% |
| Rockwell Medical Inc. | -2.220% | -11.523% | -0.116% | -52.288% | -0.807% | -75.739% | -93.713% |
| Gritstone Oncology Inc | 0.770% | 1.427% | -11.307% | -67.941% | -67.492% | -91.052% | - |
| Avid Bioservices Inc | 1.160% | 12.987% | 29.851% | -30.400% | 42.623% | -59.346% | 58.528% |
Comments
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $42.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $43.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $57.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
